CargoTek™ improves gene therapies by inducing a state of tolerance and dampening adverse pro-inflammatory reactions. Creating a state of "non-danger" for antigen presenting cells allows activation of Treg cells, a potent immune dampening cell that releases immunosuppressive cytokines.
We are leveraging our platform technology to develop a robust portfolio of next-generation biologics. In the case of gene therapy, our platform strives for multiple dosing while also enhancing efficacy of the first dose. We broaden the eligible patient population and significantly add value to the therapeutic.